A carregar...
Bioequivalence of Ertugliflozin/Sitagliptin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
A fixed‐dose combination (FDC) tablet of ertugliflozin, a selective inhibitor of sodium‐glucose cotransporter 2, and sitagliptin, a dipeptidyl peptidase‐4 inhibitor, was developed for the treatment of patients with type 2 diabetes mellitus. Four studies were conducted under fasted conditions to demo...
Na minha lista:
| Publicado no: | Clin Pharmacol Drug Dev |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6851892/ https://ncbi.nlm.nih.gov/pubmed/31219248 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.722 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|